Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

BACKGROUND: Aberrant expression of the RON receptor tyrosine kinase, a member of the MET proto-oncogene family, in breast cancer and non-small cell lung cancer (NSCLC) has therapeutic implication. Here we evaluated the efficacy of a novel anti-RON antibody-drug maytansinoid conjugate Zt/g4-DM1 for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Liang, Yao, Hang-Ping, Zhou, Yong-Qing, Zhou, Jianwei, Zhang, Ruiwen, Wang, Ming-Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840490/
https://www.ncbi.nlm.nih.gov/pubmed/27102688
http://dx.doi.org/10.1186/s13046-016-0347-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840490/
https://www.ncbi.nlm.nih.gov/pubmed/27102688
http://dx.doi.org/10.1186/s13046-016-0347-6

Ejemplares similares